Volume 11, Number 5—May 2005
Dispatch
Human T-cell Leukemia Virus Type 1 Molecular Variants, Vanuatu, Melanesia
Olivier Cassar*†, Corinne Capuano‡, Laurent Meertens†, Eliane Chungue*, and Antoine Gessain†
Figure 1
![Representative seroreactivity pattern on Western blot that contains a recombinant GD 21 (common to human T-cell leukemia virus type 1 [HTLV-1] and HTLV-2) and 2 synthetic peptides specific for HTLV-1 (MTA-1) and HTLV-2 (K55). Lane 1, HTLV-1–positive control; lane 2, HTLV-2–positive control; lane 3, HTLV-1/2 negative control; lane 4–9, 6 plasma samples from the HTLV-1–positive women of Ambae Island displaying strong reactivity to GD 21 (faint band for VAN 251), to p19 and p24 (faint band for VAN](/eid/images/04-1015-F1.gif)
Figure 1. . Representative seroreactivity pattern on Western blot that contains a recombinant GD 21 (common to human T-cell leukemia virus type 1 [HTLV-1] and HTLV-2) and 2 synthetic peptides specific for HTLV-1 (MTA-1) and HTLV-2 (K55). Lane 1, HTLV-1–positive control; lane 2, HTLV-2–positive control; lane 3, HTLV-1/2 negative control; lane 4–9, 6 plasma samples from the HTLV-1–positive women of Ambae Island displaying strong reactivity to GD 21 (faint band for VAN 251), to p19 and p24 (faint band for VAN 54), p26, p28, p32, p36 (faint bands for VAN 54 and AWM), and to MTA-1.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.